COLLEGEVILLE, Pa. ( Map ) - COLLEGEVILLE, Pa. , May 15 /PRNewswire/ — Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that PRISTIQ(TM) (desvenlafaxine), a new serotonin-norepinephrine reuptake inhibitor (SNRI) approved to treat adult patients with major depressive disorder (MDD), is now available in U.S. retail pharmacies nationwide.
Read full story
- FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder (The San Francisco Examiner)
MADISON, N.J. ( Map ) - MADISON, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a di...
- Wyeth’s Pristiq, A New Treatment For Major Depressive Disorder (Medical News Today)
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that PRISTIQTM (desvenlafaxine), a...
- Wyeth’s Pristiq: New Treatment For Major Depression
Wyeth Pharmaceuticals' PRISTIQ , a new serotonin-norepinephrine reuptake inhibitor approved to treat...
- Wyeth’s Pristiq, A New Treatment For Major Depressive Disorder
- FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder (News-Medical-Net)
Category: 
14 June 2008
Sorry, no comments yet.